Cristina Grávalos
About
Cristina Grávalos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Cristina Grávalos has authored 81 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Cristina Grávalos's work include Colorectal Cancer Treatments and Studies (55 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (23 papers). Cristina Grávalos is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (23 papers). Cristina Grávalos collaborates with scholars based in Spain, United States and France. Cristina Grávalos's co-authors include Antonio Jimeno, Pilar García‐Alfonso, Javier Sastre, Enrique Aranda, H. Cortés-Funes, Manuel Hidalgo, Rocio García‐Carbonero, Alfredo Carrato, Fernando Rivera and Luis Paz‐Ares and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Cristina Grávalos
77 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cristina Grávalos Spain | 23 | 1.7k | 960 | 514 | 426 | 319 | 81 | 2.3k | ||
| Thomas Brodowicz Austria | 28 | 2.4k 1.4× | 2.0k 2.1× | 585 1.1× | 417 1.0× | 468 1.5× | 126 | 3.4k | ||
| Takeru Wakatsuki Japan | 21 | 1.1k 0.7× | 714 0.7× | 356 0.7× | 531 1.2× | 319 1.0× | 159 | 1.8k | ||
| Maurizio Cosimelli Italy | 27 | 1.6k 1.0× | 562 0.6× | 422 0.8× | 1.1k 2.6× | 228 0.7× | 103 | 2.5k | ||
| Daisuke Takahari Japan | 29 | 1.8k 1.1× | 1.7k 1.8× | 498 1.0× | 845 2.0× | 301 0.9× | 217 | 3.1k | ||
| Philip J. Gold United States | 22 | 1.4k 0.9× | 760 0.8× | 633 1.2× | 449 1.1× | 227 0.7× | 64 | 2.2k | ||
| Matias Riihimäki Sweden | 12 | 1.4k 0.8× | 821 0.9× | 348 0.7× | 460 1.1× | 295 0.9× | 12 | 2.2k | ||
| Radka Obermannová Czechia | 18 | 1.4k 0.8× | 1.3k 1.4× | 429 0.8× | 1.1k 2.7× | 269 0.8× | 60 | 2.6k | ||
| Stephen Shibata United States | 28 | 1.2k 0.7× | 601 0.6× | 433 0.8× | 545 1.3× | 226 0.7× | 84 | 2.2k | ||
| Dae Young Zang South Korea | 27 | 1.1k 0.7× | 1.3k 1.3× | 558 1.1× | 593 1.4× | 249 0.8× | 184 | 2.6k | ||
| Carles Pericay Spain | 28 | 2.0k 1.2× | 802 0.8× | 593 1.2× | 1.1k 2.7× | 593 1.9× | 138 | 2.9k |
Countries citing papers authored by Cristina Grávalos
Since
Specialization
Citations
This map shows the geographic impact of Cristina Grávalos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Grávalos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Grávalos more than expected).
Fields of papers citing papers by Cristina Grávalos
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Cristina Grávalos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Grávalos. The network helps show where Cristina Grávalos may publish in the future.
Co-authorship network of co-authors of Cristina Grávalos
This figure shows the co-authorship network connecting the top 25 collaborators of Cristina Grávalos. A scholar is included among the top collaborators of Cristina Grávalos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristina Grávalos. Cristina Grávalos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grávalos, Cristina, Fernando Pereira, Ruth Vera, et al.. (2023). Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement. Clinical & Translational Oncology. 25(12). 3378–3394.
2.
Díaz-García, C. Vanesa, Isabel Ruppen, Pilar Ximénez‐Embún, et al.. (2022). Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Therapeutic Advances in Medical Oncology. 14. 4287498943–4287498943.
3.
García‐Alfonso, Pilar, Eduardo Díaz‐Rubio, Albert Abad, et al.. (2021). First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs & Aging. 38(3). 219–231.
4.
Elez, Élena, Cristina Grávalos, Pilar García‐Alfonso, et al.. (2021). Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. British Journal of Cancer. 126(6). 874–880.
5.
Sanmartín, O., Carmen Beato, Agustı́n España, et al.. (2019). Manejo clínico de los eventos adversos cutáneos en pacientes tratados con quimioterapia: consenso nacional de la Academia Española de Dermatología y Venereología y de la Sociedad Española de Oncología Médica. Actas Dermo-Sifiliográficas. 110(6). 448–459.
6.
Argilés, Guillem, Manuel Valladares‐Ayerbes, Cristina Grávalos, et al.. (2019). Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 30. iv135–iv135.
7.
García‐González, Xandra, María I. García, Pilar García‐Alfonso, et al.. (2018). Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacological Research. 136. 133–139.
8.
Grávalos, Cristina, O. Sanmartín, Alfonso Gúrpide, et al.. (2018). Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clinical & Translational Oncology. 21(5). 556–571.
9.
Pérez‐Segura, Pedro, Susana Monereo, R. de las Peñas, et al.. (2017). Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clinical & Translational Oncology. 19(6). 682–694.
10.
García‐Alfonso, Pilar, Ana Ruiz‐Casado, Alfredo Carrato, et al.. (2017). Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data.. Journal of Clinical Oncology. 35(15_suppl). e15019–e15019.
11.
Pellicer, Marta, Xandra García‐González, María I. García, et al.. (2017). Use of Exome Sequencing to Determine the Full Profile of Genetic Variants in the Fluoropyrimidine Pathway in Colorectal Cancer Patients Affected by Severe Toxicity. Pharmacogenomics. 18(13). 1215–1223.
12.
García‐Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2015). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 15(1). 327–327.
13.
Sastre, Javier, Guillem Argilés, Manuel Benavides, et al.. (2014). Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. Clinical & Translational Oncology. 16(11). 942–953.
14.
Maurel, Joan, et al.. (2013). SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clinical & Translational Oncology. 15(12). 991–995.
15.
Carrato, Alfredo, P. Escudero, Manuel Chaves-Conde, et al.. (2013). Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical & Translational Oncology. 15(9). 705–711.
16.
Grávalos, Cristina, Carlos García Girón, Rocio García‐Carbonero, et al.. (2012). A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clinical & Translational Oncology. 14(8). 606–612.
17.
Grávalos, Cristina & Antonio Jimeno. (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology. 19(9). 1523–1529.
18.
Grávalos, Cristina, Javier Sastre, Enrique Aranda, et al.. (2007). Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment. Journal of Clinical Oncology. 25(18_suppl). 4120–4120.
19.
Paz‐Ares, Luis, Eduardo Díaz‐Rubio, Margarita García, et al.. (2007). Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer. 6(7). 522–528.
20.
Abad, Albert, Cristina Grávalos, Albert Font, et al.. (1996). Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Investigational New Drugs. 14(2). 223–225.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Thomas Brodowicz Breakdown of academic impact, for papers by Takeru Wakatsuki Breakdown of academic impact, for papers by Maurizio Cosimelli Breakdown of academic impact, for papers by Daisuke Takahari Breakdown of academic impact, for papers by Philip J. Gold Breakdown of academic impact, for papers by Matias Riihimäki Breakdown of academic impact, for papers by Radka Obermannová Breakdown of academic impact, for papers by Stephen Shibata Breakdown of academic impact, for papers by Dae Young Zang Breakdown of academic impact, for papers by Carles Pericay